Clinical Trial Update: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. [Phase 2]

View source ↗

Summary

Phase II trial comparing everolimus with exemestane, everolimus alone, and capecitabine in advanced breast cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Everolimus (everolimus)
• Exemestane (Exemestane)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-02-26